Lentiviral vector-mediated gene transfer combined with cisplatin enhances tumor suppression in human bladder cancer cell lines

Ichikawa, Misa; Matsunaga, Wataru; Ishikawa, Takahiro; Gotoh, Akinobu

doi:10.1016/j.pmu.2019.06.002

Cited by 2 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is because it has a high antitumor effect against various cancers, including gastric, esophageal, lung, ovarian, testicular, and head and neck cancers [4][5][6][7][8][9], and potential synergistic effects when combined with other types of anticancer agents and radiation therapy [20][21]. Our research group previously reported that CDDP combined with a Lentiviral vector with tumor suppressor genes, including p53 and p16, and phosphatase and tensin homolog (PTEN)-mediated gene therapy inhibited the growth of non-muscle invasive bladder cancer (NMIBC) [22]. Despite CDDP's usefulness and versatility, its use is often discouraged based on physician judgment or rejected by patients because of the occurrence of gastrointestinal symptoms such as chemotherapy-induced nausea and vomiting (CINV) and, in severe cases, neurological disorders, immunosuppression, and renal toxicity [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer

Komura¹,

Kimura²,

Katagiri³

et al. 2023

Preprint

View full text Add to dashboard Cite

Cisplatin (CDDP) is a platinum-based drug effective against various cancers, including lung, bladder, prostate, ovarian, esophageal, stomach, and cervical cancer and malignant lymphoma. It plays a central role as the first choice in current anticancer therapy. However, CDDP causes serious side effects, such as neurological disorders, myelosuppression, and renal damage, because it is a small molecule indiscriminately distributed in normal tissues. Therefore, it is very important to prevent or attenuate CDDP toxicity. We hypothesized that liposomalization of CDDP could alleviate serious side effects. Therefore, this study aimed to evaluate the safety and efficacy of CDDP liposomes. A patient with multiple recurrent liver metastases from metastatic nasal carcinoma was administered CDDP liposomes with consent. Magnetic resonance imaging showed that the patient remained stable-diseased; however, no apparent side effects were observed, and blood draw data showed no worsening of renal function. Patients undergoing partial pancreatectomy and jejunoileal biliary anastomosis for biliary tract cancer who consented to receive CDDP liposomes demonstrated a partial response on angiographic computed tomography; however, they showed slight fatigue. To our knowledge, the present study is the first in Japan to suggest that liposomalization of CDDP may have anticancer effects while alleviating renal damage and bone marrow suppression.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer

Komura¹,

Kimura²,

Katagiri³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…34 Additionally, the antitumor effect of the combination of cisplatin which is used in the treatment of bladder cancer with p53, p16, and PTEN gene therapies was shown to be superior to classical cisplatin treatment. 35 In addition, co-administration of functionally complementary tumor suppressor genes in recent years was shown to have a major effect in triggering apoptosis.…”

Section: Tumor Suppressor Gene Activationmentioning

confidence: 99%

“…Additionally, the antitumor effect of the combination of cisplatin which is used in the treatment of bladder cancer with p53, p16, and PTEN gene therapies was shown to be superior to classical cisplatin treatment 35 …”

Section: Introductionmentioning

confidence: 99%

Gene therapy in cancer

Cesur‐Ergün,

Demir‐Dora

2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

Gene therapy, recently frequently investigated, is an alternative treatment method that introduces therapeutic genes into a cancer cell or tissue to cause cell death or slow down the growth of the cancer. This treatment has various strategies such as therapeutic gene activation or silencing of unwanted or defective genes; therefore a wide variety of genes and viral or nonviral vectors are being used in studies. Gene therapy strategies in cancer can be classified as inhibition of oncogene activation, activation of tumor suppressor gene, immunotherapy, suicide gene therapy and antiangiogenic gene therapy. In this review, we explain gene therapy, gene therapy strategies in cancer, approved gene medicines for cancer treatment and future of gene therapy in cancer. Today gene therapy has not yet reached the level of replacing conventional therapies. However, with a better understanding of the mechanism of cancer to determine the right treatment and target, in the future gene therapy, used as monotherapy or in combination with another existing treatment options, is likely to be used as a new medical procedure that will make cancer a controllable disease.

show abstract

Lentiviral vector-mediated gene transfer combined with cisplatin enhances tumor suppression in human bladder cancer cell lines

Cited by 2 publications

References 24 publications

Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer

Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer

Gene therapy in cancer

Contact Info

Product

Resources

About